This Week in Longevity: July 13, 2026 — Biological Clocks Review, Ergothioneine Convergence & More

A weekly roundup of the most interesting new research in longevity science — curated, graded, and explained in plain English.

This Week’s Simple Summary

The biggest story this week: a landmark review in Nature Medicine by Wyss-Coray (Stanford) and Topol (Scripps) takes stock of where biological aging clocks actually stand — ready for trials and risk identification, not yet for individual diagnosis. Meanwhile, a metabolomic study found that five completely different longevity interventions (rapamycin, acarbose, 17α-estradiol, canagliflozin, and caloric restriction) all converge on elevating ergothioneine, a mushroom-derived antioxidant. A new “splicing degeneration” hallmark of aging was identified — and both calorie restriction and rapamycin reverse it. And a new blood chemistry clock (BBAC) from routine labs beat PhenoAge for mortality prediction.


The detailed breakdowns continue below for those who want the full science on each finding.


Biological Aging Clocks: Where We Stand — A Nature Medicine Review

Simple Summary

Two of the biggest names in aging research published a definitive review on biological clocks. The bottom line: these clocks can now track how fast you are aging, predict disease risk, and test whether interventions work. But they are not yet accurate enough to diagnose an individual person in the clinic. The review covers clocks for brain, heart, immune system, kidney, liver, and muscle.


Published: July 9, 2026 | Nature Medicine | Tier: Gold

Key Findings

  • Clocks can now track aging pace in individuals, organs, tissues, and cells
  • Three realistic use cases: identifying high-risk individuals, serving as endpoints in clinical trials, and determining whether interventions modulate aging
  • Clock-to-clock agreement remains limited — different clocks measure different aspects
  • The review covers organ-specific clocks for brain, heart, immune system, kidney, liver, and muscle

Our Take

This is the state of the union on biological aging clocks. The fact that it is in Nature Medicine signals that biological age measurement has graduated from niche geroscience to mainstream medicine.

Source: Wyss-Coray T, Topol EJ. Nat Med. 2026 Jul 9. PMID: 42426219


Five Longevity Interventions Converge on Ergothioneine

Simple Summary

Scientists treated mice with five different anti-aging interventions — rapamycin, acarbose, a hormone, a diabetes drug, and calorie restriction — and looked for shared chemical changes across seven tissues. One molecule stood out: ergothioneine, an antioxidant found in mushrooms. All five interventions raised it in blood and brain. This is the first time anyone has shown that completely different longevity treatments share a common metabolic signature.


Published: July 2, 2026 | bioRxiv (preprint) | Tier: Silver

Key Findings

  • Metabolomic profiles could identify treated mice as recipients of a lifespan-extending intervention before survival differences emerged
  • A model trained on four interventions successfully classified mice from a fifth, unseen intervention
  • Ergothioneine was the only metabolite ranking highly in more than two tissues
  • Coordinated remodeling of lipid classes in plasma, fat, and kidney

Our Take

Ergothioneine has been a quiet player in longevity — highest in mushrooms like oyster and shiitake, and humans have a dedicated transporter for it. This study elevates it to convergence point for multiple validated longevity interventions.

Source: Badenoch B et al. bioRxiv. 2026 Jul 2. PMID: 42427596


Splicing Degeneration: A New Hallmark of Aging

Simple Summary

When your cells make proteins, they first have to splice the genetic instructions together correctly. A new study shows this splicing machinery gets sloppy with age across every tissue tested. This splicing degeneration affects important genes and gets worse as you get older. The good news: both calorie restriction and rapamycin treatment reversed it.


Published: June 29, 2026 | bioRxiv (preprint) | Tier: Silver

Key Findings

  • Alternative splicing becomes less precise with age — reading frames shift, protein domains get misconfigured
  • Affected genes are disproportionately involved in RNA metabolism and antigen presentation
  • Both calorie restriction and rapamycin treatment reduced splicing degeneration

Our Take

A new dimension to molecular aging: it is not just which genes are on or off, but how precisely they are processed. CR and rapamycin reverse it — splicing quality is a meaningful target.

Source: Zhang S et al. bioRxiv. 2026 Jun 29. PMID: 42427714


Blood Biochemistry Age Clock (BBAC): Biological Age from Routine Labs

Simple Summary

Researchers built a biological age calculator using 11 standard blood tests — the same ones your doctor already orders. Tested on over 500,000 people in the UK Biobank, it predicted mortality better than the leading blood-based clock (PhenoAge). Because it uses routine labs, this could make biological age testing free and widely accessible.


Published: July 12, 2026 | Mech Ageing Dev | Tier: Silver

Key Findings

  • 11 biomarkers from standard metabolic panels and CBCs
  • UK Biobank: BBAC beat PhenoAge for mortality prediction
  • Validated on NHANES against PCAge and LinAge clocks
  • Interpretable: shows which biomarkers add or subtract years

Our Take

Epigenetic clocks cost $200-500. A free clock from routine labs removes the cost barrier. Caveat: developed by a commercial company; independent replication needed.

Source: Selb J et al. Mech Ageing Dev. 2026 Jul 12. PMID: 42437599


Also Noteworthy This Week

  • New senolytic compound UCM-17017 shows promise for pulmonary fibrosis — selectively kills senescent lung cells, improved outcomes in a mouse model. PMID: 42427232
  • Deleting the ASAP3 gene extends healthspan in mice — normalizes actin dynamics, restores autophagy, reduces liver senescence. PMID: 42431471
  • NAD+ activates REST to protect mitochondria in Alzheimer’s disease — connects NAD+ decline to neurodegeneration via mitochondrial quality control. PMID: 42423068
  • Multi-modal longevity protocol pilot: 2-3 years biological age reduction in 17 weeks — small trial (n=14), no control group, company-funded. PMID: 42428158

Disclaimer: This digest provides information for educational purposes, not medical advice. Always consult your healthcare provider before starting any supplement, medication, or significant lifestyle change. Full disclaimer

Scroll to Top